A Phase 1, open label study of intravenous GSK3745417 to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and determine RP2D & schedule in participants with relapsed or refractory Myeloid Malignancies including AML and HR MDS

Trial Identifier: 209809
Sponsor: GlaxoSmithKline
Start Date: September 2022
Primary Completion Date: March 2024
Study Completion Date: March 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Canada, ON Toronto, ON, Canada, M5G 2M9
Germany Dresden, Germany, 01307
Germany Leipzig, Germany, 04103
Italy Meldola FC, Italy, 47014
Italy Perugia, Italy, 06132
Italy Roma, Italy, 00168
Netherlands ROTTERDAM, Netherlands, 3015 GD
Spain Madrid, Spain, 28033
Spain Madrid, Spain, 28040
Spain Valencia, Spain, 46026